A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (TAURUS)

October 5, 2020 updated by: AVEO Pharmaceuticals, Inc.

A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects With Metastatic Renal Cell Carcinoma

Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC). Approximately 160 subjects will be stratified for ECOG score (0 vs 1) and histology (clear cell vs non-clear cell) and then will be randomized 1:1 to 1 of 2 treatment arms. The study consists of two 12-week treatment periods with a 1-week washout in between. Subjects will receive double-blind (over-encapsulated) tivozanib hydrochloride and sunitinib sequentially. The study is designed to compare subject treatment preference, as well as overall safety and tolerability, frequency of dose modifications and kidney-specific health outcomes/QoL.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
58

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Antwerp, Belgium
      • Brussels, Belgium
  • France
      • Bordeaux, France
      • Caen, France
      • Lyon, France
      • Paris, France
  • Germany
      • Berlin, Germany
      • Hamburg, Germany
      • Hannover, Germany
      • Heidelberg, Germany
      • Munich, Germany
  • Italy
      • Aviano, Italy
      • Pavia, Italy
      • Rome, Italy
  • Spain
      • Barcelona, Spain
      • Madrid, Spain
      • Pamplona, Spain
      • Valencia, Spain
  • United Kingdom
      • Cambridge, United Kingdom
      • London, United Kingdom
      • Manchester, United Kingdom
    • Scotland
      • Glasgow, Scotland, United Kingdom
    • Wales
      • Swansea, Wales, United Kingdom
  • United States
    • California
      • Los Angeles, California, United States, 90001
    • Georgia
      • Albany, Georgia, United States, 31701
      • Atlanta, Georgia, United States, 30301
    • Illinois
      • Chicago, Illinois, United States, 60007
    • Indiana
      • Indianapolis, Indiana, United States, 46077
    • Louisiana
      • Shreveport, Louisiana, United States, 71101
    • Massachusetts
      • Worcester, Massachusetts, United States, 01601
    • Minnesota
      • Minneapolis, Minnesota, United States, 55111
    • New York
      • New York, New York, United States, 10001
    • Ohio
      • Columbus, Ohio, United States, 43004
    • Oregon
      • Portland, Oregon, United States, 97035
    • South Carolina
      • Charleston, South Carolina, United States, 29401
      • Myrtle Beach, South Carolina, United States, 29572
    • Texas
      • San Antonio, Texas, United States, 78006
    • Wisconsin
      • Madison, Wisconsin, United States, 53558

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Unresectable mRCC
  • Histologically or cytologically confirmed RCC of any histology
  • Subjects with or without prior nephrectomy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • Any prior systemic therapy for treatment of mRCC (including investigational or licensed drugs that target VEGF or VEGF receptors/pathway, or are mammalian target of rapamycin [mTOR] inhibitors)
  • Central nervous system malignancies or metastases
  • Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders
  • Significant serum chemistry or urinalysis abnormalities
  • Significant cardiovascular disease, including symptomatic left ventricular ejection fraction or baseline LVEF of ≤ institutional lower limit of normal, uncontrolled hypertension, myocardial infarction or severe angina within 6 months prior to administration of first dose of study drug, history of class III or IV congestive heart failure, or history of serious ventricular arrhythmia, cardiac arrhythmias, or coronary or peripheral bypass graft within 6 months of screening
  • Corrected QT interval (QTc) of >480 msec using Bazett's formula
  • Currently active second primary malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Tivozanib Hydrochloride
1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
Drug: Tivozanib
Other Names:
  • Tivozanib Hydrochloride
ACTIVE_COMPARATOR: Sunitinib
50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
Drug: Sunitinib
Other Names:
  • Sutent

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Proportion of Subjects Who Prefer Tivozanib Hydrochloride or Sunitinib
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of Subjects With AEs and SAEs
Time Frame: Up to 25 weeks
Number of subjects with serious and non-serious adverse events.
Up to 25 weeks
Number of Subjects With Dose Reductions
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Dose Interruptions
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Grade 3/4 Hematology Abnormalities
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Grade 3/4 Chemistry Abnormalities
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Grade 3/4 Coagulation Abnormalities
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Grade 3/4 Urinalysis Abnormalities
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Number of Subjects With Grade 3/4 Thyroid Function Abnormalities
Time Frame: Up to 25 weeks
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Up to 25 weeks
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Time Frame: Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
Change From Baseline in FACT Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS)
Time Frame: Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
Change From Baseline in Functional Assessment of Cancer Therapy-Diarrhea (FACT-D)
Time Frame: Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
Change From Baseline in Euro Quality of Life - 5 Dimensions (EQ-5D)
Time Frame: Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment
The study was terminated prior to completing enrollment; due to low enrollment, no data was collected for this outcome measure.
Baseline, Weeks 1, 4, 10, 14, 17, 23, and End of Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
AVEO Pharmaceuticals, Inc.

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Astellas Pharma Inc

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Michael Needle, MD, AVEO Pharmaceuticals, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2012

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2014

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2014

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 23, 2012

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 27, 2012

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 28, 2012

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 27, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 5, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • AV-951-12-205

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings